Clinical Trials Logo

Metaplasia clinical trials

View clinical trials related to Metaplasia.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06282484 Completed - Gastric Cancer Clinical Trials

A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous Lesions

Start date: September 1, 2022
Phase:
Study type: Observational

To explore the effects of gastric xanthoma on gastric cancer and its precancerous lesions, so as to better prevent the occurrence and development of gastric cancer.

NCT ID: NCT06269380 Completed - Clinical trials for Intestinal Metaplasia

Evaluation of Antral Biopsies Obtained in Normal Esophagogastroduodenoscopy

Start date: February 13, 2024
Phase: N/A
Study type: Interventional

Esophagogastroduodenoscopy (EGD) is commonly performed in patients presenting with abdominal pain and dyspeptic symptoms, serving as a valuable diagnostic and therapeutic tool. While various methods are available for biopsy sampling when mucosal pathology is observed during EGD, the practice of obtaining biopsies from endoscopically normal mucosa remains controversial. Although there is literature suggesting that routine biopsies from the antrum and duodenum for surveillance purposes increase costs, pathological findings can sometimes be detected in areas that appear normal on mucosal examination, leading to potential changes in treatment approach if biopsies are obtained. In this study, a retrospective evaluation of the prevalence of various pathologies detected in biopsies obtained from endoscopically normal mucosa in patients who underwent EGD was reported as normal.

NCT ID: NCT05345314 Completed - Clinical trials for Gastric Intestinal Metaplasia

Endoscopic Grading of Intestinal Metaplasia

Start date: March 1, 2022
Phase:
Study type: Observational

Long-term Helicobacter pylori infection causes premalignant gastric conditions, such as atrophic gastritis and intestinal metaplasia. Image-enhanced endoscopy techniques such as narrow-band imaging (NBI) and magnifying endoscopy improve the diagnosis of gastric intestinal metaplasia (GIM). However, there are no comparative data on the utility of NBI and magnifying endoscopy for diagnosing GIM.

NCT ID: NCT05288153 Completed - Clinical trials for Gastric Intestinal Metaplasia

Metformin Efficacy and Safety for Gastric Intestinal Metaplasia

Start date: April 1, 2022
Phase: Phase 4
Study type: Interventional

Gastric intestinal metaplasia significantly increases the risk of gastric cancer. Metformin, a biguanide, which is widely used for treating diabetes mellitus, has recently been suggested to have a suppressive effect on tumorigenesis and cancer cell growth. The investigators devised a prospective randomized controlled trial to evaluate the chemopreventive effect of metformin against gastric intestinal metaplasia and the safety of this drug in non-diabetic gastric intestinal metaplasia patients.

NCT ID: NCT04348266 Completed - Treatment Clinical Trials

RFA for GIM Treatment

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Use radiofrequency ablation (RFA) for Gastric intestinal metaplasia (GIM) treatment.

NCT ID: NCT04296513 Completed - Clinical trials for Helicobacter Pylori Infection

Diagnosis of Gastritis, H. Pylori Infection and Atrophic Gastritis in Dyspeptic Patients

Start date: March 1, 2020
Phase:
Study type: Observational

Gastric cancer is the third most common cause of cancer-related death worldwide (1). Upper endoscopy is necessary to detect neoplastic macroscopic features at an early stage, but subtle abnormalities in the gastric mucosa are often missed or misdiagnosed (1). Helicobacter pylori (Hp) is involved in the pathogenesis of gastric diseases, such as, peptic ulcers, gastric lymphoma, and gastric cancer. Therefore, the necessity to recognize malignant gastric lesions at an early stage is imperative.

NCT ID: NCT03976739 Completed - Gastric Cancer Clinical Trials

Study on the Effect of Bile Reflux on Gastric Cancer and Its Precancerous Lesions: a Cross-sectional Study.

Start date: June 17, 2019
Phase:
Study type: Observational

To explore the effects of bile reflux on gastric cancer and its precancerous lesions, so as to better prevent the occurrence and development of gastric cancer.

NCT ID: NCT03672708 Completed - Clinical trials for Gastric Intestinal Metaplasia

Confocal Laser Endomicroscopy With Cresyl Violet for in Vivo Diagnosis of Gastric Intestinal Metaplasia

Start date: September 16, 2018
Phase: N/A
Study type: Interventional

Confocal laser endomicroscopy (CLE) is a novel endoscopic system which can provide approximately 1000-fold magnification of the gastrointestinal mucosa. Previous studies have demonstrated its diagnostic value for Gastric intestinal metaplasia (GIM) with the use of a contrast agent.Recently, Cresyl violet (CV) has been used in CLE to visualize tissue architecture in human ileum, colon or myenteric plexus.No investigation has reported the characterization of GIM imaged with CLE when using CV as staining dye

NCT ID: NCT03380052 Completed - Stomach Neoplasms Clinical Trials

OLGA and OLGIM Stage System for Gastric Cancer

Start date: February 2006
Phase:
Study type: Observational

To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification in South Korea. Also attempted to estimate synergistic interaction among the several risk factors to help establish surveillance strategy.

NCT ID: NCT03188406 Completed - Gastric Cancer Clinical Trials

Gastric Cancer Precursor Lesions (GCPL) Study

Start date: May 2, 2017
Phase:
Study type: Observational

Background: Gastric cancer is a leading cause of cancer deaths around the world. This disease is a serious problem in places like East Asia, Central and South America, and Eastern Europe. Researchers want to study the causes of gastric cancer and its precursors. They want to reduce the number of people with stomach cancer. Objectives: To learn more about bacteria factors and other causes of gastric cancer. To study potential markers associated with precancerous gastric lesions (intestinal metaplasia). Eligibility: Adults ages 40-70 years at certain hospitals in Chile who: Are going to have upper gastrointestinal endoscopies OR have stomach cancer and need surgery Design: Participants will give gastric tissue samples. Some participants will donate a portion of the stomach tissue that is removed as part of their clinical care. Participants will give access to reports of their stomach exam. They will allow researchers to photograph the microscope slides of their tissue samples. Participants will answer questions. The topics of the questions include: Age, height, weight Education Habits including tobacco and alcohol Personal and family history of disease Reproductive history Diet Some participants will give blood, urine, saliva, and stool samples. Study staff will collect the blood. They will tell the participants how to collect the other samples themselves.